Dan Hennings

Preclinical data highlights the therapeutic potential of Ashvattha’s novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based on symptom reduction in the EAE model Ashvattha’s 18F-OP-801 PET imaging agent shows reduction in neuroinflammation following treatment with CSF1R dendranib Presentation by Stanford University collaborator nominated for Brain Imaging Council Young Investigator Award at … Read more

Presentations highlight the therapeutic potential of Ashvattha’s novel CSF1R tyrosine kinase inhibitor (CSF1R dendranib) for multiple sclerosis (MS) based on symptom reduction in the EAE preclinical model CSF1R dendranib (H74DS3M8) clinical candidate is orally bioavailable and designed to avoid safety concerns of other CSF1R tyrosine kinase inhibitors using Ashvattha’s proprietary hydroxyl dendrimer nanomedicine technology Reduction … Read more

REDWOOD CITY, Calif., February 14, 2024 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that members of its senior management team will participate in two upcoming investor conferences. Conference Details:  BIO CEO & Investor Conference … Read more

REDWOOD CITY, Calif., January 4, 2024 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointment of Mehdi Paborji, Ph.D., as Senior Vice President of Technical Operations. Dr. Paborji will oversee technical operations, CMC, and … Read more

REDWOOD CITY, Calif., November 20, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that members of its senior management team will participate in two upcoming ophthalmology conferences. Conference Details: BTIG 3rd Annual Ophthalmology Day  … Read more

REDWOOD CITY, Calif., October 9, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointment of Sakura Minami, Ph.D., as Vice President of Translational Medicine and Nonclinical Development and Sarah Thayer as Head … Read more

Data demonstrated that ASH41020, a novel CSFR1 tyrosine kinase inhibitor ‘dendranib’, directs macrophage polarization toward the anti-inflammatory M2 phenotype ASH41020 treatment lessened disease severity in a preclinical model of multiple sclerosis (MS) to a similar extent to fingolimod, an approved MS treatment Study suggests ASH41020 is a potent anti-inflammatory and immunomodulatory agent that warrants further … Read more

Data will showcase anti-inflammatory and immunomodulatory effects of ASH41020, a novel CSFR1 tyrosine kinase inhibitor ‘dendranib’, in a mouse model of multiple sclerosis REDWOOD CITY, Calif., August 15, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing a new class of nanomedicine therapeutics, today announced a poster presentation of preclinical data on ASH41020, its new … Read more

REDWOOD CITY, Calif., May 31, 2023 – Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced the appointments of Paul E. Cayer as Chief Financial Officer and Omega Therapeutics President and CEO, Mahesh Karande to the … Read more

Data demonstrated that a single oral dose of D-4517.2 significantly reduced choroidal neovascularization (CNV) lesions to a level comparable to D-4517.2 delivered subcutaneously and Aflibercept administered intravitreally at the same mass dose in a laser-induced CNV mouse model  Findings from a second preclinical study in a VLDLR−/− mouse model demonstrated oral and subcutaneous administration of … Read more